New Market Research Report, “Nuclear Receptors: The Pipeline Outlook,” just released by CHI

Oct. 7, 2010 - PRLog -- Cambridge Healthtech Institute is pleased to announce the release of it’s latest Insight Pharma Report, “Nuclear Receptors: The Pipeline Outlook.” This business intelligence report examines the development pipeline of candidate drugs targeting nuclear receptors and includes figures and tables summarizing the activity in this therapeutic target family.

Nuclear receptors are a super family of intra-cellular receptors present in most animal species. They mediate the transcriptional responses to metabolic ligands. In humans, 48 nuclear receptors have been identified. These are characterized as belonging to one of 11 subgroups. The most active targets are the estrogen receptors, glucocorticoid receptors, and progesterone receptors. Some 13% of drugs approved for sale in the United States are nuclear receptors with 15 of these drugs in the top 200 prescribed medicines. These top drugs represented $27.5 billion of sales revenue in 2009.

The top-selling drug in this category is GlaxoSmithKline’s drug Advair/Seretide with sales of $7.8 billion in 2009. The major indications for these drugs include asthma, COPD, diabetes type II, hyperlipidemia, contraception, hormone replacement therapy, prostate cancer, and osteoporosis. Clearly nuclear receptors are an important class of targets for pharmaceutical development.

Key topics covered in this report include:
-- Current top nuclear receptor drugs and indications
-- Preclinical and clinical developments
-- Potential of novel nuclear receptor targets
-- Profiles of company development activity
-- New indications for nuclear receptor-targeted drugs

For more information and to purchase this report, go to:
http://www.insightpharmareports.com/reports_report.aspx?i...

Related Reports:
Epigenetic Drug & Diagnostic Pipelines
http://www.insightpharmareports.com/reports_report.aspx?i...

Kinase Therapeutics: Pipeline Assessment and Commercial Prospects
http://www.insightpharmareports.com/reports_report.aspx?r...

Contact:
James Prudhomme
Cambridge Healthtech Institute
Tel: +1 781-972-5486
jprudhomme@healthtech.com

# # #

Insight Pharma Reports are written by experts in consulting and industry who collaborate with us to provide a series of reports that evaluate the salient issues in pharmaceutical technology, business, and therapy markets.